|View printer-friendly version|
Real H. Renaud to Retire by End of 2010
Renaud Retirement and Molho Promotion
Real H. Renaud, Corporate Executive Vice President and President, Global
Research Models and Services, has announced his intention to retire by
the end of 2010. As a first step in a planned twelve to eighteen month
transition of Mr. Renaud’s responsibilities, we are pleased to announce
the promotion of
Mr. Renaud said, “Davide has been instrumental in the ongoing success of
RMS Europe and the expansion of service offerings in that region. His
client-focused approach has enabled him to drive continuing growth in
Dr. Molho joined Charles River Italy in 1999, and was promoted to Director of Operations for RMS Italy in 2002. In 2005, his role was expanded to include all French RMS operations and in 2007, he became Corporate Vice President, European Research Models and Services, with responsibility for all European RMS operations.
Mr. Foster also said, “In today’s challenging economic environment, we are continually identifying new strategies to enhance customer satisfaction, improve efficiencies and strengthen business operations. Our clients are transforming their business models, and in order to continue to provide the superior client service which they have come to expect from us, we must evolve with them. The PCS organizational changes will enhance our ability to provide customers with a centralized, integrated global approach to their drug development programs across all business segments, and the Sales realignment will provide our clients access to the full breadth of Charles River’s extensive product and service portfolio through a central point of contact. The PCS changes will also facilitate the implementation of operational efficiencies identified through our Six Sigma initiatives, which we believe will enable us to improve the cost effectiveness of our business while driving sales growth.”
Restructure of Preclinical Services
Through the restructure of the PCS business, we have created a dual-accountability structure with both global functional teams and site-level management, the purpose of which is to elevate the harmonization and integration of all services across the PCS organization. By doing so, we will enable the seamless and consistent delivery of services to our clients worldwide. In combination with the Sales organization realignment, we also expect this restructure to facilitate interaction between the Company and our clients, and to enhance their access to the services offered across our global PCS operation. From individual study through program management, we will provide services tailored to meet each client’s particular requirements, utilizing expertise from various facilities to support client programs, regardless of the specific site at which the program is resident.
We expect a significant benefit from this restructuring initiative will be the ease with which we will be able to leverage our Lean Six Sigma and other process harmonization efforts to standardize on best-in-class processes across the PCS organization. This will enable us to deliver increasing value to our clients in support of their efforts to reduce drug development cycle time and cost.
Under the new global operations structure, members of the existing senior PCS management team have broad responsibility for functional areas and site-specific operations, including:
Sales Organization Realignment
Beginning immediately and extending through year end, Charles River is implementing a realignment of our Sales organization. The goal of the realignment is to migrate from a sales approach which focuses on our portfolio of products and services to one focused on value-based solutions by customer segment. We expect this approach to enhance client interaction and improve our ability to address their individual needs. We believe these changes will strengthen our existing client relationships and enable us to attract new clients as we endeavor to drive sales growth.
Through this realignment, Charles River is establishing a three-pronged sales organization which addresses global biopharmaceutical companies, small and mid-size pharmaceutical and biotechnology companies, and the academic and government sector. Each of these market segments has particular needs which can be more effectively addressed by dedicated sales resources with knowledge of and access to Charles River’s entire product and services portfolio, both PCS and RMS.
Caution Concerning Forward-Looking Statements
This news release includes forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as “anticipate,”
“believe,” “expect,” “will,” “may,” “estimate,” “plan,” “outlook,” and
“project” and other similar expressions that predict or indicate future
events or trends or that are not statements of historical matters. These
statements also include statements regarding the impact of specific
actions intended to improve overall operating efficiencies and
profitability (including the restructuring of our PCS segment and our
Sales organization realignment), the RMS succession plan, and the future
demand for drug discovery and development products and services
(particularly in light of the challenging economic environment),
including the outsourcing of these services and present spending trends
by our customers. Forward-looking statements are based on Charles
River’s current expectations and beliefs, and involve a number of risks
and uncertainties that are difficult to predict and that could cause
actual results to differ materially from those stated or implied by the
forward-looking statements. Those risks and uncertainties include, but
are not limited to: a decrease in research and development spending, a
decrease in the level of outsourced services, or other cost reduction
actions by our customers; the ability to convert backlog to sales;
special interest groups; contaminations; industry trends; new
displacement technologies; USDA and
About Charles River
Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our approximately 8,700 employees worldwide are focused on providing clients with exactly what they need to improve and expedite the discovery, development through first-in-human evaluation, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Charles River Laboratories International, Inc.
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
Amy Cianciaruso, 781-222-6168
Associate Director, Public Relations